Why Praxis’ latest FDA win could matter far beyond one genetic epilepsy program
Find out how Praxis’ FDA Breakthrough Therapy Designation for elsunersen could reshape SCN2A-DEE epilepsy treatment and ASO development.
Pharma & Biotech
Pharma & Biotech
Could Praxis Precision Medicines’ Phase 3 ulixacaltamide data redefine the treatment pathway in essential tremor?
Praxis Precision Medicines’ positive Phase 3 ulixacaltamide data could reshape essential tremor treatment. Discover what this means for neurology and investors.